Search clinical trials for: Cytoxan

Total 1516 results

Dana-Farber Cancer Institute
Incyte Corporation

Active, not recruiting

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Inflammatory Breast Cancer (IBC)

United States
Providence Health & Services

Active, not recruiting

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Breast Cancer

United States
Spectrum Health Hospitals
Millennium Pharmaceuticals, Inc.

Completed

Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis

Hematological Malignancy

United States
Spanish Breast Cancer Research Group
Sanofi; Pfizer; Hoffmann-La Roche

Completed

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Breast Cancer

Spain
Alla Keyzner

Completed

VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies

Myelodysplastic Syndromes | Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Acute Leukemia in Remission | Hematological Malignancy | Acute Lymphoblastic Leukemia in Remission

United States
National Cancer Institute (NCI)

Terminated

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Cervical Cancer | Pancreatic Cancer | Ovarian Cancer | Lung Cancer | Mesothelioma

United States
Masonic Cancer Center, University of Minnesota

Terminated

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

Breast Cancer

United States
Masonic Cancer Center, University of Minnesota

Withdrawn

Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
ETOP IBCSG Partners Foundation

Completed

Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer (22-00)

Breast Cancer

Italy, Switzerland, Australia, Peru, South Africa, Chile, Belgium, Brazil, Romania, Hungary, Nigeria
Immatics Biotechnologies GmbH
National Cancer Institute (NCI)

Terminated

Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Glioblastoma

United States
University of Washington
National Cancer Institute (NCI)

Withdrawn

Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer

United States
Radboud University Medical Center
Sanofi; Amgen

Completed

Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer. (INTENS)

Breast Cancer

Netherlands
M.D. Anderson Cancer Center

Active, not recruiting

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Recurrent Anaplastic Large Cell Lymphoma and other conditions

United States
M.D. Anderson Cancer Center

Completed

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Leukemia

United States
M.D. Anderson Cancer Center

Completed

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Lymphoma | Leukemia

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

Lymphoma

United States
University of Ulm

Completed

Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result

Acute Myeloid Leukemia

Germany, Austria
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Juno Therapeutics, Inc.

Completed

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
Ortho Biotech, Inc.

Completed

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Lymphoma

United States
UbiVac
National Cancer Institute (NCI); Mayo Clinic; Louisiana State University Health... and other collaborators

Completed

Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma

Sarcoma

United States, Canada, Australia, Puerto Rico
Sumithira Vasu

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditions

United States
Fred Hutchinson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Terminated

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Adult Acute Lymphoblastic Leukemia | Refractory Diffuse... and other conditions

United States
M.D. Anderson Cancer Center
Amgen

Completed

Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
Bayer

Terminated

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Lymphoma

United States
University of Kansas Medical Center

Recruiting

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC (NeoTRACT)

Breast Cancer | Triple Negative Breast Cancer

United States
Hadassah Medical Organization

Recruiting

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Non Small Cell Lung Cancer | Metastatic Cancer | Triple Negative Breast Cancer | Sarcoma, Synovial | Ovary Cancer | Sarcoma,Soft Tissue | Melanoma Stage IV | Bladder Urothelial Carcinoma | Neuroblastoma, Metastatic

Israel
Loyola University

Recruiting

Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide

Acute Myeloid Leukemia | Chronic Lymphocytic Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Non-hodgkin Lymphoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb; National Cancer Institute (NCI)

Recruiting

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Pancreatic Cancer

United States
St. Jude Children's Research Hospital

Active, not recruiting

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Hodgkin Lymphoma | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Chronic Myeloid Leukemia (CML) | NK-Cell Leukemia | Non Hodgkin Lymphoma (NHL) | Juvenile Myelomonocytic Leukemia (JMML)

United States
Spanish Breast Cancer Research Group
Sanofi

Completed

Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment

Breast Neoplasms

Spain
Spanish Breast Cancer Research Group
Bristol-Myers Squibb

Completed

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

Breast Cancer

Spain
M.D. Anderson Cancer Center
Genentech, Inc.; OSI Pharmaceuticals

Completed

FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years

Chronic Lymphocytic Leukemia

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...

Completed

Preoperative Herceptin and Navelbine for Breast Cancer

Breast Cancer | Stage II Breast Cancer | Stage III Breast Cancer

United States
M.D. Anderson Cancer Center
CLL Global Research Foundation Alliance

Withdrawn

Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)

Leukemia
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
European Society for Blood and Marrow Transplantation
Pierre Fabre Medicament

Terminated

Dose-reduced Versus Standard Conditioning in MDS/sAML (RICMAC)

Myelodysplastic Syndromes | Secondary Acute Myeloid Leukemia

Germany, Italy, Netherlands, Russian Federation
Sunesis Pharmaceuticals

Completed

Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Bellicum Pharmaceuticals, Inc.

Not yet recruiting

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Colorectal Cancer | Minimal Residual Disease

United States
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, Spain, Australia, United States, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Poland, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom
University College Hospital, Ibadan
University of Chicago; Lagos State University; Obafemi Awolowo University Teaching... and other collaborators

Recruiting

MicroRNA Profiles in Triple Negative Breast Cancer (TARMAC)

Triple Negative Breast Cancer

Nigeria
Baylor College of Medicine
National Cancer Institute (NCI); The Methodist Hospital Research Institute; Center... and other collaborators

Active, not recruiting

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN (GRAIN)

Neuroblastoma

United States
M.D. Anderson Cancer Center

Completed

Primary Breast Cancer Occurring Concomitant With Pregnancy

Breast Cancer | Pregnancy

United States
Masonic Cancer Center, University of Minnesota

Completed

Allogeneic Transplantation For Severe Osteopetrosis

Severe Osteopetrosis

United States
St. Jude Children's Research Hospital
CURE Childhood Cancer, Inc.

Completed

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Neuroblastoma

United States
National Cancer Institute (NCI)

Terminated

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Metastatic Uveal Melanoma | Metastatic Ocular Melanoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma

Metastatic Melanoma

United States
Medical College of Wisconsin

Recruiting

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

Graft-versus-host Disease

United States
Karolinska University Hospital

Recruiting

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Melanoma

Sweden

Search clinical trials for: Cytoxan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Colombia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations